Bio-Medical Applications Of Georgia, Inc. is a medicare approved dialysis facility center in Austell, Georgia and it has 17 dialysis stations. It is located in Cobb county at 3602 Marathon Circle, Austell, GA, 30106. You can reach out to the office of Bio-Medical Applications Of Georgia, Inc. at (770) 222-0253. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Bio-Medical Applications Of Georgia, Inc. has the following ownership type - Profit. It was first certified by medicare in April, 2016. The medicare id for this facility is 852507 and it accepts patients under medicare ESRD program.
| Name | Bio-Medical Applications Of Georgia, Inc. |
|---|---|
| Location | 3602 Marathon Circle, Austell, Georgia |
| No. of Dialysis Stations | 17 |
| Medicare ID | 852507 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 3602 Marathon Circle, Austell, Georgia, 30106 | |
| (770) 222-0253 | |
| Not Available |
News Archive
Michael H. Criqui, M.D., M.P.H., of the University of California, San Diego, and colleagues determined the independent associations of coronary artery calcium (CAC) volume and CAC density with cardiovascular disease events.
Cardio3 BioSciences, a leader in the discovery and development of engineered cell therapies, today confirmed plans to open a new U.S.-based manufacturing facility in Rochester, Minnesota. The facility will support the Company's current and anticipated manufacturing needs in the United States for both the Phase III clinical trial evaluating lead cardiovascular product candidate C-Cure (CHART-2), and its recently acquired CAR T-cell therapies' portfolio.
For millions of people around the world being sick doesn't mean making a trip to the local pharmacy for medicines like Advil and Nyquil. Instead it means turning to the forest to provide a pharmacopeia of medicines to treat everything from tooth aches to chest pains.
People who narrowly avoid disaster do not necessarily escape tragedy unharmed, and their knowledge of the victims' fate shapes how survivors respond to traumatic events, according to the results of a new paper by a University at Buffalo psychologist that explores the effects of near-miss experiences associated with the 9/11 terrorist attacks.
› Verified 6 days ago
| NPI Number | 1053780338 |
| Organization Name | Fresenius Medical Care Of Powder Springs |
| Doing Business As | Bio-medical Applications Of Georgia, Inc. |
| Address | 3602 Marathon Cir Austell, Georgia, 30106 |
| Phone Number | (770) 222-0253 |
News Archive
Michael H. Criqui, M.D., M.P.H., of the University of California, San Diego, and colleagues determined the independent associations of coronary artery calcium (CAC) volume and CAC density with cardiovascular disease events.
Cardio3 BioSciences, a leader in the discovery and development of engineered cell therapies, today confirmed plans to open a new U.S.-based manufacturing facility in Rochester, Minnesota. The facility will support the Company's current and anticipated manufacturing needs in the United States for both the Phase III clinical trial evaluating lead cardiovascular product candidate C-Cure (CHART-2), and its recently acquired CAR T-cell therapies' portfolio.
For millions of people around the world being sick doesn't mean making a trip to the local pharmacy for medicines like Advil and Nyquil. Instead it means turning to the forest to provide a pharmacopeia of medicines to treat everything from tooth aches to chest pains.
People who narrowly avoid disaster do not necessarily escape tragedy unharmed, and their knowledge of the victims' fate shapes how survivors respond to traumatic events, according to the results of a new paper by a University at Buffalo psychologist that explores the effects of near-miss experiences associated with the 9/11 terrorist attacks.
› Verified 6 days ago
| Dialysis patients with Hemoglobin data | 32 |
News Archive
Michael H. Criqui, M.D., M.P.H., of the University of California, San Diego, and colleagues determined the independent associations of coronary artery calcium (CAC) volume and CAC density with cardiovascular disease events.
Cardio3 BioSciences, a leader in the discovery and development of engineered cell therapies, today confirmed plans to open a new U.S.-based manufacturing facility in Rochester, Minnesota. The facility will support the Company's current and anticipated manufacturing needs in the United States for both the Phase III clinical trial evaluating lead cardiovascular product candidate C-Cure (CHART-2), and its recently acquired CAR T-cell therapies' portfolio.
For millions of people around the world being sick doesn't mean making a trip to the local pharmacy for medicines like Advil and Nyquil. Instead it means turning to the forest to provide a pharmacopeia of medicines to treat everything from tooth aches to chest pains.
People who narrowly avoid disaster do not necessarily escape tragedy unharmed, and their knowledge of the victims' fate shapes how survivors respond to traumatic events, according to the results of a new paper by a University at Buffalo psychologist that explores the effects of near-miss experiences associated with the 9/11 terrorist attacks.
› Verified 6 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 72 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 601 |
| Percentage of adult patients getting regular hemodialysis at the center | |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Michael H. Criqui, M.D., M.P.H., of the University of California, San Diego, and colleagues determined the independent associations of coronary artery calcium (CAC) volume and CAC density with cardiovascular disease events.
Cardio3 BioSciences, a leader in the discovery and development of engineered cell therapies, today confirmed plans to open a new U.S.-based manufacturing facility in Rochester, Minnesota. The facility will support the Company's current and anticipated manufacturing needs in the United States for both the Phase III clinical trial evaluating lead cardiovascular product candidate C-Cure (CHART-2), and its recently acquired CAR T-cell therapies' portfolio.
For millions of people around the world being sick doesn't mean making a trip to the local pharmacy for medicines like Advil and Nyquil. Instead it means turning to the forest to provide a pharmacopeia of medicines to treat everything from tooth aches to chest pains.
People who narrowly avoid disaster do not necessarily escape tragedy unharmed, and their knowledge of the victims' fate shapes how survivors respond to traumatic events, according to the results of a new paper by a University at Buffalo psychologist that explores the effects of near-miss experiences associated with the 9/11 terrorist attacks.
› Verified 6 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Bio-Medical Applications Of Georgia, Inc. with elevated calcium levels.
| Patients with hypercalcemia | 74 |
| Hypercalcemia patient months | 611 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | |
| Patients with Serumphosphor | 79 |
| Patients with Serumphosphor less than 3.5 mg/dL | |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | |
| Patients with Serumphosphor greater than 7 mg/dL |
News Archive
Michael H. Criqui, M.D., M.P.H., of the University of California, San Diego, and colleagues determined the independent associations of coronary artery calcium (CAC) volume and CAC density with cardiovascular disease events.
Cardio3 BioSciences, a leader in the discovery and development of engineered cell therapies, today confirmed plans to open a new U.S.-based manufacturing facility in Rochester, Minnesota. The facility will support the Company's current and anticipated manufacturing needs in the United States for both the Phase III clinical trial evaluating lead cardiovascular product candidate C-Cure (CHART-2), and its recently acquired CAR T-cell therapies' portfolio.
For millions of people around the world being sick doesn't mean making a trip to the local pharmacy for medicines like Advil and Nyquil. Instead it means turning to the forest to provide a pharmacopeia of medicines to treat everything from tooth aches to chest pains.
People who narrowly avoid disaster do not necessarily escape tragedy unharmed, and their knowledge of the victims' fate shapes how survivors respond to traumatic events, according to the results of a new paper by a University at Buffalo psychologist that explores the effects of near-miss experiences associated with the 9/11 terrorist attacks.
› Verified 6 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 84 |
| Patient months included in arterial venous fistula and catheter summaries | 490 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer |
News Archive
Michael H. Criqui, M.D., M.P.H., of the University of California, San Diego, and colleagues determined the independent associations of coronary artery calcium (CAC) volume and CAC density with cardiovascular disease events.
Cardio3 BioSciences, a leader in the discovery and development of engineered cell therapies, today confirmed plans to open a new U.S.-based manufacturing facility in Rochester, Minnesota. The facility will support the Company's current and anticipated manufacturing needs in the United States for both the Phase III clinical trial evaluating lead cardiovascular product candidate C-Cure (CHART-2), and its recently acquired CAR T-cell therapies' portfolio.
For millions of people around the world being sick doesn't mean making a trip to the local pharmacy for medicines like Advil and Nyquil. Instead it means turning to the forest to provide a pharmacopeia of medicines to treat everything from tooth aches to chest pains.
People who narrowly avoid disaster do not necessarily escape tragedy unharmed, and their knowledge of the victims' fate shapes how survivors respond to traumatic events, according to the results of a new paper by a University at Buffalo psychologist that explores the effects of near-miss experiences associated with the 9/11 terrorist attacks.
› Verified 6 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | |
| Hospitalization Rate in facility | (Not Available) |
| Hospitalization Rate: Upper Confidence Limit | |
| Hospitalization Rate: Lower Confidence Limit |
News Archive
Michael H. Criqui, M.D., M.P.H., of the University of California, San Diego, and colleagues determined the independent associations of coronary artery calcium (CAC) volume and CAC density with cardiovascular disease events.
Cardio3 BioSciences, a leader in the discovery and development of engineered cell therapies, today confirmed plans to open a new U.S.-based manufacturing facility in Rochester, Minnesota. The facility will support the Company's current and anticipated manufacturing needs in the United States for both the Phase III clinical trial evaluating lead cardiovascular product candidate C-Cure (CHART-2), and its recently acquired CAR T-cell therapies' portfolio.
For millions of people around the world being sick doesn't mean making a trip to the local pharmacy for medicines like Advil and Nyquil. Instead it means turning to the forest to provide a pharmacopeia of medicines to treat everything from tooth aches to chest pains.
People who narrowly avoid disaster do not necessarily escape tragedy unharmed, and their knowledge of the victims' fate shapes how survivors respond to traumatic events, according to the results of a new paper by a University at Buffalo psychologist that explores the effects of near-miss experiences associated with the 9/11 terrorist attacks.
› Verified 6 days ago